Shots:

• The P-III (TROPiCS-02) study evaluating Trodelvy vs CT (eribulin, capecitabine, gemcitabine, or vinorelbine) in a ratio (1:1) in 543 patients with HR+/HER2- metastatic breast cancer with HER2-low & IHC 0 status prior treated with endocrine therapy, CDK4/6 inhibitors & two to four lines of CT
• The results showed an improvement in OS & the safety profile was consistent with prior studies with no new safety signals. The results will be presented at an upcoming medical conference
• The company has submitted an sBLA of Trodelvy to the US FDA & the results will also be shared with health authorities outside the US. The therapy is also being studied for other TNBC & metastatic UC populations along with a range of tumor types

Ref: Gilead Sciences, Inc. | Image: Gilead Sciences, Inc.